From Capital Infusion to Innovation-Driven Growth: How Chinese Biotechs Make the 'Leap of Faith'
As China’s healthcare payment system reform continues to deepen, the development trajectories of many Chinese biotech companies have been affected to varying degrees. To address this challenge, some biotechs have leveraged their accumulated strengths to promote innovative drugs into the global market through license-out deals, thereby realizing a new development pattern characterized by mutual reinforcement between domestic and international dual circulation. Others have targeted major unmet medical needs within China, shortening drug R&D cycles through license-in arrangements to consolidate their competitive advantages and further enrich their R&D pipelines.
Data shows that since 2017, the number of cross-border transactions involving Chinese biotech companies has risen rapidly, with transaction amounts increasing day by day. Moreover, there is a growing trend of collaborations focused on early-stage innovative projects or technology platforms. Notable examples include Johnson & Johnson’s in-licensing of Legend Biotech’s BCMA CAR-T therapy; Biogen’s acquisition of rights to InnoCare Pharma’s next-generation BTK inhibitor for multiple sclerosis (MS); AbbVie’s in-licensing of I-Mab’s differentiated CD47 monoclonal antibody and bispecific antibody; and Zai Lab’s acquisition of rights to niraparib in mainland China, Hong Kong, and Macao.
These success stories hold significant implications for domestic biotech companies seeking breakthroughs. On one hand, they signify that these companies’ innovation capabilities and commercialization prowess have gained recognition, enabling a self-sustaining cycle of revenue generation and laying a solid foundation for subsequent R&D efforts. On the other hand, they can accelerate the global market entry of their proprietary new drugs while facilitating the introduction of foreign innovative therapies into China, thereby helping to overcome domestic limitations and maximize the value of innovative medicines.
It is foreseeable that, for a considerable period to come, leveraging cross-border business development (BD) to drive their own growth will remain a priority for many Chinese biotech companies. Therefore, it is essential to summarize the experiences and lessons learned by pioneers in the BD field, so as to provide insights and reflections for latecomers pursuing internationalization and for the innovative drug industry’s continued ascent.
To this end, DXY Insight Online Lecture Series, in collaboration with VBInsight, has specially invited Mr. Chen Rulai, Co-founder and COO of InnoLake Pharma, to deliver a talk themed “Cross-border Business Development: An Innate Gene of Biotech.” Drawing on real-world cases, he will distill the evolving trends and detailed processes of cross-border transactions for biotech companies, helping you gain a more thorough understanding of all aspects of overseas market expansion for biotechs.
Course Topic: Cross-Border Business Development: An Innate Trait of Biotech
Course Guests:Chen Rulai, Co-founder and COO of InnoLake Pharma
Mr. Chen Rulai holds an educational background in biological sciences and business management, having studied at Wuhan University, the Chinese Academy of Sciences, the University of Florida in the United States, and the School of Management at Fudan University. Prior to co-founding the Company, he spent nearly 20 years working in corporate strategy, business development, research and development (R&D), and general management at several R&D-driven biopharmaceutical enterprises specializing in drugs and vaccines. He also has two years of experience in venture capital investment within the biomedical sector.
Course Duration: Tuesday, April 26, 2022, 10:00–11:00
Course Highlights：
1. Analyze Changes in Cross-Border Biotech Transactions and Gain Insights into Future Trends
2. Summarize the key points of cross-border transaction processes in the biotech industry and gain an in-depth understanding of transaction rules
3. Analyze typical cross-border business development (BD) cases and provide practical, in-depth insights
Registration Method: Scan the QR code below to register for free.
Scan the QR code to join the group and chat with more pharmaceutical peers about various topics:
Insight Database is a data intelligence platform established by DXY in the pharmaceutical field, encompassing comprehensive lifecycle data on domestic and international drugs, including regulatory submission progress, clinical trials, marketed products, consistency evaluation, and market access. It also features unique integrated analysis modules for drug screening, corporate analysis, global new drugs, and clinical trial results. Accessible via PC and WeChat Mini Programs, it is dedicated to providing efficient, convenient, and feature-rich data intelligence query services to participants in the pharmaceutical industry.
VBioPharma is a media and research platform under VCBeat, dedicated to the biopharmaceutical sector. It empowers innovators and entrepreneurs in communicating their value through two key dimensions: content and operations. In terms of content, it primarily features corporate profiles of frontier companies, investment and financing updates, R&D progress, reviews of outstanding domestic and international case studies, and industry reports on niche sectors. On the operational front, through its branded column “VB Think Tank,” it focuses on practical challenges, discusses industrial trends, and fosters tangible collaborations through intellectual exchange. Featured Specials: [IPO in Progress] [Financial Report Analysis] [iPSC] [Radiopharmaceuticals] [Small-Molecule Degraders] [Upstream Tools].